One Technology-Many Applications
PerSimiO's unique solution, Simfini, will perform highly accurate, patient specific bone strength analysis based on CT scans, leveraging the Company's immense knowledge in biomechanics, applied mathematics, finite element analysis, and machine-learning.
The novel technology will create a virtual 3D model of the bone and calculate the risk of fracture based on the patient's normal physical activities and weight.
At the end of the process, a complete report including a fracture risk assessment is sent to the physician for review.
Simfini-SENIOR
32 million people in the US experience loss of bone mineral density (osteoporosis) while aging, with elevated risk of fracture. There are over 400,000 cases of femur fractures in the US every year.
Simfini-SENIOR will identify which patients are at high risk of hip fracture – enabling better planning, treatment and oversight to minimize the risk.
Diabetes patients are at higher risk of hip fracture. While patients with diabetes type II have twice the risk of a normal person to fracture the hip, diabetes type I have six times the risk to fracture. There is no marker or diagnostic test to show that they are at risk and DXA (dual-energy x-ray absorptiometry) has false results, with normal to high bone density readings, which are not correlated to actual fractures. Furthermore, there are no monitoring tools to assess drug treatment effectiveness, or other treatment given to the patient that, according to their doctor, are at a higher risk to fracture.
Simfini-SENIOR will identify which patients are at high risk of contralateral hip fracture – enabling better planning, treatment and oversight to minimize the risk.
Simfini-TUMOR
Simfini-TUMOR offers accurate assessment of the strength of bone affected by primary or metastatic tumors to determine the likelihood of fracture enabling the MD to decide if the patient requires prophylactic surgery or if non-surgical treatments are sufficient for the patient. There are more than 90,000 cases of metastasized cancer in the femur annually.
By accurately determining whether or not the tumor has weakened the patient's bone to the point that a pathologic fracture is imminent, physicians benefit from a assessment of the necessity of prophylactic surgery. Simfini-TUMOR offers a highly reliable prediction model and methodology reducing the number of unnecessary surgeries with the related cost, rehabilitation and complications while at the same time ensuring that those that at high risk of a pathologic fracture are operated on prophylactically.
